Brief: Kymera Therapeutics Announces U.S. FDA Fast Track Designation For KT-621, A First-In-Class, Oral STAT6 Degrader For The Treatment Of Atopic Dermatitis

Kymera Therapeutics

11/12/2025 12:47

Dec 11 (Reuters) - Kymera Therapeutics Inc KYMR.O:

KYMERA THERAPEUTICS ANNOUNCES U.S. FDA FAST TRACK DESIGNATION FOR KT-621, A FIRST-IN-CLASS, ORAL STAT6 DEGRADER FOR THE TREATMENT OF ATOPIC DERMATITIS

KYMERA THERAPEUTICS INC - KT-621 PHASE 2B AD TRIAL DATA EXPECTED BY MID-2027

KYMERA THERAPEUTICS INC: BREADTH PHASE 2B TRIAL IN ASTHMA ON TRACK TO INITIATE IN 1Q26

Source text: ID:nGNXbxYdsh

Further company coverage: KYMR.O

 ((Reuters.Briefs@thomsonreuters.com;))